CINECA IRIS Institutional Research Information System

SABA, Francesca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.289
EU - Europa 2.655
AS - Asia 2.400
SA - Sud America 396
OC - Oceania 48
AF - Africa 43
Continente sconosciuto - Info sul continente non disponibili 5
Totale 8.836
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.909
CN - Cina 1.184
IT - Italia 530
SE - Svezia 380
JP - Giappone 335
DE - Germania 271
MX - Messico 243
SG - Singapore 228
FR - Francia 200
IE - Irlanda 156
UA - Ucraina 147
AT - Austria 145
BR - Brasile 143
GB - Regno Unito 141
FI - Finlandia 110
CA - Canada 101
IN - India 97
ES - Italia 94
KR - Corea 89
RU - Federazione Russa 82
TW - Taiwan 74
PL - Polonia 72
ID - Indonesia 67
VN - Vietnam 66
PE - Perù 65
CO - Colombia 64
TR - Turchia 57
BE - Belgio 55
EC - Ecuador 51
HK - Hong Kong 47
AU - Australia 45
GR - Grecia 44
PT - Portogallo 31
CL - Cile 30
SI - Slovenia 29
TH - Thailandia 29
NL - Olanda 28
CH - Svizzera 27
AR - Argentina 24
IR - Iran 22
RO - Romania 21
DK - Danimarca 20
MY - Malesia 19
PH - Filippine 14
EG - Egitto 13
IL - Israele 13
CZ - Repubblica Ceca 12
GT - Guatemala 12
HU - Ungheria 10
VE - Venezuela 10
BY - Bielorussia 8
HN - Honduras 8
NO - Norvegia 8
MM - Myanmar 7
RS - Serbia 7
AZ - Azerbaigian 6
BG - Bulgaria 6
BO - Bolivia 6
PK - Pakistan 6
QA - Qatar 6
SK - Slovacchia (Repubblica Slovacca) 6
LB - Libano 5
LK - Sri Lanka 5
LV - Lettonia 5
SA - Arabia Saudita 5
SN - Senegal 5
ZA - Sudafrica 5
CR - Costa Rica 4
EU - Europa 4
JO - Giordania 4
PA - Panama 4
SY - Repubblica araba siriana 4
BF - Burkina Faso 3
CV - Capo Verde 3
HR - Croazia 3
NI - Nicaragua 3
NZ - Nuova Zelanda 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
BA - Bosnia-Erzegovina 2
CD - Congo 2
DZ - Algeria 2
GE - Georgia 2
GH - Ghana 2
KE - Kenya 2
KZ - Kazakistan 2
LT - Lituania 2
MA - Marocco 2
PR - Porto Rico 2
SV - El Salvador 2
UZ - Uzbekistan 2
CW - ???statistics.table.value.countryCode.CW??? 1
DO - Repubblica Dominicana 1
IS - Islanda 1
KW - Kuwait 1
LU - Lussemburgo 1
MO - Macao, regione amministrativa speciale della Cina 1
MT - Malta 1
NA - Namibia 1
RE - Reunion 1
Totale 8.833
Salva come PNG Salva come JPEG
Città #
Chandler 437
Beijing 315
Ann Arbor 198
Singapore 173
Dublin 155
Vienna 136
Ashburn 122
Torino 112
Dearborn 110
Santa Clara 108
Fairfield 103
Redwood City 93
Villeurbanne 92
Wilmington 83
Nyköping 81
Shanghai 80
Woodbridge 79
Tokyo 78
Houston 74
Jacksonville 74
Guangzhou 67
Turin 64
Medford 58
Ottawa 58
Princeton 53
Taipei 48
Columbus 47
Cambridge 46
Pisa 44
Seattle 41
Lima 40
Dong Ket 39
Warsaw 38
Nanjing 37
Brussels 33
Hangzhou 33
Wuhan 33
Changsha 31
Chongqing 31
Fremont 31
Jakarta 31
Rome 30
Boardman 29
Milan 29
New York 29
Munich 28
São Paulo 26
Bogotá 25
Helsinki 24
Chengdu 23
Mexico City 23
London 22
Santiago 22
Hefei 20
Tianjin 20
Boston 19
Shenyang 18
Athens 17
Glasgow 17
Guayaquil 17
Istanbul 17
Saint Petersburg 17
Jinan 16
Mexico 16
Paris 16
Central 15
Zhengzhou 15
Guadalajara 14
Kunming 14
Los Angeles 14
Osaka 14
Bangkok 13
Frankfurt am Main 13
Fuzhou 13
Hyderabad 12
Monterrey 12
Buenos Aires 11
Changchun 11
Guatemala City 11
Kuala Lumpur 11
Norwalk 11
San Diego 11
Toronto 11
Valencia 11
Ankara 10
Arequipa 10
Caruaru 10
Cuenca 10
Mumbai 10
Quito 10
Belo Horizonte 9
Berlin 9
Chihuahua City 9
Hanoi 9
Hong Kong 9
Washington 9
Zurich 9
Barcelona 8
Brisbane 8
Duncan 8
Totale 4.510
Salva come PNG Salva come JPEG
Nome #
Diabetic ketoacidosis with SGLT2 inhibitors 2.520
Fatty liver and chronic kidney disease: Novel mechanistic insights and therapeutic opportunities 828
Angiotensin II Type 1 Receptor rs5186 Gene Variant Predicts Incident NAFLD and Associated Hypertension: Role of Dietary Fat-Induced Pro-Inflammatory Cell Activation 431
Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances 282
Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial 243
Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease 219
LIVER DAMAGE CAN BE ASSOCIATED WITH DEREGULATION OF THE DE NOVO LIPOGENESIS PATHWAY IN SUBJECTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 179
Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load 173
Plasma Selenoprotein P levels are related to adipose tissue insulin resistance, composition of free fatty acids and liver fibrosis in non-diabetic patients with Non Alcoholic Fatty Liver Disease 167
TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD. 153
Alteration in glucose metabolism after an oral glucose load in patients with non-alcoholic fatty liver disease. 151
Advanced glycation end products and their related signaling cascades in adult survivors of childhood Hodgkin lymphoma: A possible role in the onset of late complications 146
Metabolic handling of an oral fat load in NAFLD patients. 138
Alteration in glucose metabolism after an oral glucose load and relationship with liver damage in patients with NAFLD. 136
Subjects with non alcoholic fatty liver disease (NAFLD) display increased visceral and pancreatic fat associated with worse metabolic profile. 134
LIPIDOMICS REVEALS THAT LOW PLASMA UNSATURATED TO SATURATED FAT RATIOS ARE BIOMARKERS OF NAFLD AND LIVER DAMAGE 129
Effects of glucose and fat load on oxidative stress in patients with non-alcoholic fatty liver disease. 128
Effects of 6 months of resveratrol versus placebo on pentraxin 3 in patients with type 2 diabetes mellitus: a double-blind randomized controlled trial 127
Impact of fat versus glucose load on oxidative stress in non-alcoholic fatty liver disease. 126
Alteration in lipid metabolism after an oral fat load in subjects with NAFLD. 126
Recent Insight into the Role of Fibrosis in Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma 124
Validation of surrogate indexes of peripheral and hepatic insulin resistance and evaluation of their utility as non-invasive predictors of histological features in patients with Non-Alcoholic Fatty Liver Disease 121
Adverse impact of visceral fat on lipid and metabolic profile in fatty liver disease 119
Matabolomic analysis identifies new biomarkers of liver damage in NAFLD 118
Alteration in lipid metabolism after an oral fat load in non-alcoholic fatty liver disease. 112
Oxidative stress-inducible factors promote liver fibrosis in patients with Non-Alcoholic Fatty Liver Disease. 111
DEREGULATION OF DE NOVO LIPOGENESIS CAN BE ASSOCIATED WITH LIVER DAMAGE IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 111
Quantitative and qualitative analysis of plasma free fatty acids and their impact on liver damage in NAFLD patients. 108
INCIDENCE AND SEVERITY OF NONALCOHOLIC FATTY LIVER DISEASE ASSOCIATED WITH IMPAIRED LIPID AND GLUCOSE METABOLISM ARE PREDICTED BY SREBF POLYMORPHISM. 106
Alteration in lipid metabolism after an oral fat load in patients with NAFLD. 103
Effect of lectin-like oxidized LDL receptor-1 polymorphism on liver disease, glucose homeostasis, and postprandial lipoprotein metabolism in nonalcoholic steatohepatitis. 102
After oral fat load NAFLD subjects and healthy controls show different serum free fatty acid trends. 101
Serum free fatty acid composition is associated with different degrees of fibrosis. 101
SREBF-1C polymorphism affects postprandial lipid metabolism in NAFLD subjects. 100
Compositional Characteristics and Antioxidant Activity of Edible Rose Flowers and Their Effect on Phenolic Urinary Excretion 100
Emerging Liver-Kidney Interactions in Nonalcoholic Fatty Liver Disease 99
Postprandial cholesterol metabolism: a clue to the impact of TM6SF2 rs58542926 variant on liver and cardiovascular disease in NAFLD? 98
LECTIN-LIKE OXIDIZED LDL RECEPTOR-1 (LOX-1) POLYMORPHISM IS INDEPENDENTLY ASSOCIATED WITH LIVER HISTOLOGY IN NASH. 85
Peripheral insulin resistance rather than hepatic is a primary defect in non obese, non diabetic, non dyslipidemic NAFLD patients: correlation with liver damage. 82
MERTK rs4374383 variant predicts incident nonalcoholic fatty liver disease and diabetes Role of mononuclear cell activation and adipokine response to dietary fat 81
Peripheral insulin resistance rather than hepatic is a primary defect in non obese, non diabetic, non dyslipidemic nafld patients: correlation with liver damage. 80
Metabolic alterations of lipid kinetics in NAFLD patients and their contribution to liver damage. 79
GLUCOSE HOMEOSTASIS AND POSTPRANDIAL LIPOPROTEIN METABOLISM IN NONALCOHOLIC STEATOHEPATITIS (NASH) ARE AFFECTED BY LECTIN-LIKE OXIDIZED LDL RECEPTOR-1 (LOX-1) POLYMORPHISM. 71
Metabolic alterations of lipid kinetics in NAFLD patients and their contribution to liver damage. 68
Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression 65
Endoscopic duodenal mucosa ablation techniques for diabetes and nonalcoholic fatty liver disease: A systematic review 22
Analytical and clinical comparison between two different analytical methods for the measurement of circulating insulin in patients with metabolic-dysfunction associated steatotic liver disease 16
Effect of phospholipid curcumin Meriva® on liver histology and kidney disease in nonalcoholic steatohepatitis a randomized, double-blind, placebo-controlled trial 16
Molecular Mechanisms of Curcumin in the Pathogenesis of Metabolic Dysfunction Associated Steatotic Liver Disease 15
EFFICACIA DELLA CURCUMINA NEL TRATTAMENTO DELLA STEATOSI EPATICA NON ALCOLICA (NAFLD). EFFECT OF CURCUMIN FOR NONALCOHOLIC STEATO-EPATITIS 8
Totale 9.058
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.066
article - articoli 0
book - libri 0
conference - conferenze 8.748
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.814
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020546 0 0 0 0 0 115 91 55 70 108 44 63
2020/2021892 60 68 20 67 99 76 37 48 73 100 115 129
2021/20221.515 60 99 79 123 118 83 155 96 82 180 257 183
2022/20231.643 137 158 98 155 141 274 117 129 137 93 109 95
2023/20241.384 137 160 111 108 107 166 100 94 16 112 141 132
2024/20251.220 142 183 227 184 363 121 0 0 0 0 0 0
Totale 9.058